EZH2 has been extensively studied in several cancers and has been shown to play a significant role in the development of breast cancer, lymphoma, gastric cancers, esophageal cancer, non small-cell lung carcinomas, soft tissue sarcomas, salivary gland adenoid cystic carcinoma, and head and neck carcinomas. This evidence concerns the gene EZH2 and cancer.